Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase 2 Study of CP-945,598 in NASH
2008-004088-21Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of otenabant in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in liver histology (NAS) at 48 weeks. Started Jul 2008; status: terminated.
02
Drugs
otenabant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2008-004088-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004088-21.